Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Celgene International II Sàrl
Femme et Homme Max 99 ans
Celgene International II Sàrl
MAJ Il y a 4 ans
A study to assess the safety and tolerability of durvalumab as monotherapy and in combination therapy in people with lymphoma or chronic lymphocytic leukemia
Dose finding part (Phase 1): - To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Celgene International II Sàrl
MAJ Il y a 4 ans
A study to assess the safety and clinical activity of durvalumab as combination therapy on previously untreated people with high risk diffuse large b-cell lymphoma
The primary objective of the study is to explore the clinical activity of durvalumab (MEDI4736) in combination with R-CHOP (non-activated B-cell) or R2-CHOP (activated B-cell) followed by durvalumab c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Celgene International II Sàrl
MAJ Il y a 4 ans
A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from the body
The primary objectives of the study are: •To determine how the drug [14C]-RPC1063 moves through the body and how fast it is removed from the body •To assess the amount of radioactivity found in bloo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations